

RECEIVED
CENTRAL FAX CENTER
JUN 23 2008

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) A noninvasive cancer screening method comprising
 - a) providing a mixture of proteomic cancer markers from different types of cancer cells, said mixture containing proteomic cancer markers identified and markers not yet identified;
 - b) forming polyclonal antibodies against the mixture;
 - 5 c) forming a reagent from said polyclonal antibodies;
 - d) obtaining a saliva sample from a human not diagnosed with cancer;
 - e) bringing said saliva sample together with the reagent to form an assay sample, and
 - f) assaying the assay sample by simple ELISA test to determine whether an immunological reaction has occurred in the assay sample,
- 10 wherein ELISA test results higher than a predetermined value are indicative of a positive screening test for cancer.
2. (Previously presented) A method as in claim 1 wherein, in the ELISA test, the human saliva sample is coated on a plate prior to being brought together with the reagent.
3. (Previously presented) A method as in claim 2 wherein the ELISA test results are titer.

4 - 7 (canceled)

8. (Previously presented) A method as in claim 1 wherein the polyclonal antibodies are produced in animals.

9. (Previously presented) A method as in claim 8 further comprising separating blood containing the polyclonal antibodies from the animals and separating serum containing the polyclonal antibodies therefrom.

10. (Previously presented) A method as in claim 9 further comprising forming the reagent from the serum.

11. (Previously presented) A method as in claim 1 further comprising centrifuging a human saliva specimen to separate out cells and mucin and collecting the supernatant to form the human saliva sample.

12. (Previously presented) A method as in claim 11 further comprising collecting the human saliva specimen.

13 - 15 (canceled)

16. (Previously presented) A non-invasive cancer screening method comprising

a) providing a mixture of proteomic cancer markers obtained from breast, liver, colon, and ovarian cancers, said mixture containing proteomic cancer markers identified and markers not yet identified;

5 b) forming polyclonal antibodies against the mixture;

- c) forming a reagent from said polyclonal antibodies;
 - d) obtaining a saliva specimen from a human not diagnosed with cancer;
 - e) forming a saliva sample from the saliva specimen;
 - f) bringing the saliva sample together with the reagent to form an assay sample; and
 - 10 g) assaying the assay sample by simple ELISA titer test to determine whether an immunological reaction has occurred in the assay sample,
- wherein ELISA titer test results of greater than 1:1,000 are indicative of a positive screening test for cancer.
17. (Previously presented) A method as in claim 16 wherein, in the simple ELISA test, the saliva sample is coated on a plate prior to being brought together with the reagent .
18. (canceled)
19. (canceled)
20. (Previously presented) A method as in claim 1 further comprising, in a case where the ELISA test results are indicative of a positive screening test for cancer,
- a) obtaining a second saliva specimen from the human,
 - b) forming a second saliva sample from the second saliva specimen,
 - 5 c) separating the second saliva sample into a plurality of portions,
 - d) bringing each portion of the second saliva sample together with a reagent produced by providing a mixture of proteomic cancer markers identified and markers not yet identified from a

single type of cancer cells, forming polyclonal antibodies against the mixture, and forming the reagent from the polyclonal antibodies, to form an assay sample; and

- 10 e) conducting a simple ELISA test on the assay sample,
wherein an ELISA test result higher than a predetermined value is indicative of a positive screening test for proteomic markers of said cancer cell type.

21 - 23 (canceled)

24. (currently amended) A method as in claim 20

wherein the ~~plurality of proteomic cancer markers from different types of cancer cells~~
~~comprise proteomic cancer cell markers made~~ single type of cancer cells is selected from
the group consisting of a breast cancer cell line, a lung cancer cell line, a stomach cancer
cell line, a liver cancer cell line, a colon cancer cell line, an ovarian cancer cell line, a
cervical cancer cell line, a mouth/pharynx cancer cell line, a skin cancer cell line, a
pancreatic cancer cell line, a testes cancer cell line, a brain tumor cell line, and a prostate
cancer cell line .